Market Cap: $8.39B
TI
TG Therapeutics, Inc.
TGTX
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $8.39B
TG Therapeutics (Ticker: TGTX) announces a significant development in its pipeline with the initiation of a Phase 2 clinical trial for its subcutaneous formulation of BRIUMVI. This follows promising t…
TG Therapeutics (Ticker: TGTX) is making strides in the biotechnology sector, particularly in developing BRIUMVI for treating autoimmune conditions like multiple sclerosis (MS). Recent updates regardi…
TG Therapeutics (Ticker: TGTX) has raised its revenue guidance for the year 2026, highlighting its strong performance in the pharmaceutical sector. The company attributes this positive outlook primari…
Earnings Reports Mirror Industry Resilience Amid Economic Challenges In the healthcare sector, companies are poised to showcase their performance amidst ongoing economic uncertainties. Specifically, M…
TG Therapeutics' Navigating the Innovative Landscape of Treatment Development In the quickly evolving field of biopharmaceuticals, TG Therapeutics demonstrates a strong commitment to advancing treatme…
TG Therapeutics: Pioneering Innovations in Lymphoma Treatment TG Therapeutics remains at the forefront of innovating therapies aimed at treating lymphomas, specifically with its lead drug, umbralisib.…
Insider Selling Sparks Investor Scrutiny at TG Therapeutics On November 25, 2023, TG Therapeutics reveals a notable insider transaction involving its Director, Yann Echelard, who discloses the sale of…
Insider Selling Raises Questions About TG Therapeutics' Future Recently, TG Therapeutics (NASDAQ: TGTX) faces scrutiny following an insider sell disclosed by Director Yann Echelard on November 25, 202…
Insider Selling Sparks Scrutiny at TG Therapeutics Amidst Ongoing Development Efforts On November 25, 2023, TG Therapeutics, a biopharmaceutical company specializing in innovative treatments for cance…
TG Therapeutics: Pioneering Advances in Multiple Sclerosis Treatment TG Therapeutics is making significant strides in the treatment landscape for multiple sclerosis (MS) with its innovative therapies.…
TG Therapeutics: Pioneering Innovations in Biopharmaceuticals As TG Therapeutics prepares to release its quarterly earnings report on November 3, 2025, the focus shifts to the company’s innovative app…
TG Therapeutics Prepares for Upcoming Earnings Report: Focus on Innovative Drug Development TG Therapeutics, a biopharmaceutical company known for its pioneering work in treatments for cancer and auto…
Climb Bio's Innovative Approach to Autoimmune Diseases Climb Bio is making headlines with its lead candidate, budoprutug, which is currently under development for a range of autoimmune conditions. Thi…
Climb Bio's Innovative Approach to Autoimmune Diseases Climb Bio (NASDAQ:CLYM) garners attention in the biotechnology sector as William Blair initiates coverage of the company, spotlighting its lead c…
Climb Bio's Innovative Approach to Autoimmune Diseases: A Promising Development In the rapidly evolving biotechnology sector, Climb Bio (NASDAQ: CLYM) emerges as a noteworthy contender with its lead c…
TG Therapeutics Strengthens Market Position with Enhanced Share Repurchase Program TG Therapeutics Inc. (TGTX) takes a significant step in its financial strategy by announcing the authorization of an…
TG Therapeutics Strengthens Commitment to Shareholder Value with New Buyback Authorization TG Therapeutics Inc. (TGTX) announces a significant strategic move by authorizing an additional $100 million…
TG Therapeutics Faces Challenges Amid Earnings Shortfall TG Therapeutics, a biopharmaceutical company specializing in innovative therapies for hematologic malignancies and autoimmune diseases, experie…
TG Therapeutics Faces Earnings Setback Amid Market Fluctuations In the latest trading session, TG Therapeutics experiences a notable decline in its stock price, dropping nearly 15% after the company r…
TG Therapeutics Prepares for Critical Earnings Announcement Amid Competitive Landscape TG Therapeutics (TGTX) stands on the brink of revealing its quarterly earnings on August 4, 2025, a moment antici…
TG Therapeutics: A Promising Player in the Therapeutic Landscape TG Therapeutics is gaining attention in the biopharmaceutical sector for its innovative approach to treating hematologic malignancies.…
Navigating Therapeutic Innovation: TG Therapeutics' Promising Pipeline TG Therapeutics stands at the forefront of innovation in the biopharmaceutical sector, particularly in the development of targete…
TG Therapeutics Faces Scrutiny Following Insider Sale by Director In a recent filing with the Securities and Exchange Commission (SEC), Yann Echelard, Director of TG Therapeutics (TGTX), reports the s…